https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Thu, 09 Jul 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-07-09/#supremo-pmrt-critique https://oncbrain.oncologytoolkit.com/2026-07-09/#supremo-pmrt-critique Thu, 09 Jul 2026 00:00:00 GMT breast [Challenges SOC] Editorial critique: chest-wall-only RT cut 10yr CW recurrence 1.1% vs 2.5% (HR 0.45) but RNI was prohibited. Eligible: Post-mastectomy breast, node-negative high-risk or 1-3 positive nodes https://oncbrain.oncologytoolkit.com/2026-07-09/#sbrt-uir-prostate-astro24 https://oncbrain.oncologytoolkit.com/2026-07-09/#sbrt-uir-prostate-astro24 Thu, 09 Jul 2026 00:00:00 GMT prostate Conference education session on SBRT for UIR prostate: 5 fractions over 1-2wks, 1-2% bothersome toxicity vs 10-30% with 45-fraction 2D era. https://oncbrain.oncologytoolkit.com/2026-07-09/#hydra-marcap https://oncbrain.oncologytoolkit.com/2026-07-09/#hydra-marcap Thu, 09 Jul 2026 00:00:00 GMT prostate [Confirmatory] No PFS difference for either isodose (HR 0.92) or dose-escalated MHFRT (HR 0.94), but escalation raises late G2+ GI (OR 1.48). Eligible: Localised prostate cancer, definitive external-beam RT